BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 1841751)

  • 1. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
    Geller J
    J Androl; 1991; 12(6):364-71. PubMed ID: 1769904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
    Sandow J; von Rechenberg W; Engelbart K
    Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximal androgen blockade versus total androgen suppression.
    Dumez H; Van Poppel H; Baert L; Paridaens R
    Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug treatment of prostatic carcinoma].
    Witjes JA; Debruyne FM
    Ned Tijdschr Geneeskd; 1997 Sep; 141(39):1855-8. PubMed ID: 9545743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is dehydroepiandrosterone a hormone?
    Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
    J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Science behind total androgen blockade: from gene to combination therapy.
    Labrie F; Bélanger A; Dupont A; Luu-The V; Simard J; Labrie C
    Clin Invest Med; 1993 Dec; 16(6):475-92. PubMed ID: 8013153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma of the prostate: general concepts.
    Rioja LA; Sanz J
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):2-8. PubMed ID: 1948119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy for prostate cancer.
    Sagalowsky AI
    Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.